{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:15Z","timestamp":1793449095356,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001167","name":"The Larry L Hillblom Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R21HD113234"],"award-info":[{"award-number":["R21HD113234"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI154659"],"award-info":[{"award-number":["U01AI154659"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA227481"],"award-info":[{"award-number":["R01CA227481"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["R01HG010863"],"award-info":[{"award-number":["R01HG010863"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ebiom.2026.106227","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:54:07Z","timestamp":1775606047000},"page":"106227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-0584","authenticated-orcid":false,"given":"Cosmin A.","family":"Bejan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Venkateswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa A.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-9906","authenticated-orcid":false,"given":"G Scott","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Brondfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3479-0630","authenticated-orcid":false,"given":"Kimberly","family":"de Dios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-1378","authenticated-orcid":false,"given":"Eric","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Quandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ebiom.2026.106227_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106227_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ebiom.2026.106227_bib3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106227_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.ebiom.2026.106227_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10124","key":"10.1016\/j.ebiom.2026.106227_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106227_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106227_bib8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"Jama Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106227_bib9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00262-021-02880-0","article-title":"Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events","volume":"70","author":"Nashed","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106227_bib10","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad019","article-title":"Dearth of ICD codes for complications of immune checkpoint inhibitors impedes clinical care and research","volume":"7","author":"Cheung","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ebiom.2026.106227_bib11","article-title":"Identification and characterization of immune checkpoint inhibitor-induced toxicities from electronic health records using natural language processing","volume":"8","author":"Barman","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.ebiom.2026.106227_bib12","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.24.00326","article-title":"Enhancing precision in detecting severe immune-related adverse events: comparative analysis of large language models and international classification of disease codes in patient records","volume":"42","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106227_bib13","author":"Mittal"},{"key":"10.1016\/j.ebiom.2026.106227_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/CCI.20.00109","article-title":"Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning","volume":"5","author":"Gupta","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.ebiom.2026.106227_bib15","author":"Radford"},{"key":"10.1016\/j.ebiom.2026.106227_bib16","series-title":"Proceedings of the 34th International Conference on Neural Information Processing Systems","article-title":"Language models are few-shot learners","author":"Brown","year":"2020"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106227_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jama.2024.21700","article-title":"Testing and evaluation of health care applications of large language models: a systematic review","volume":"333","author":"Bedi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2026.106227_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2025.106091","article-title":"Performance and improvement strategies for adapting generative large language models for electronic health record applications: a systematic review","volume":"205","author":"Du","year":"2026","journal-title":"Int J Med Inform"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106227_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41746-023-00957-x","article-title":"Zero-shot interpretable phenotyping of postpartum hemorrhage using large language models","volume":"6","author":"Alsentzer","year":"2023","journal-title":"NPJ Digit Med"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106227_bib21","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41598-025-86632-5","article-title":"Large language models improve the identification of emergency department visits for symptomatic kidney stones","volume":"15","author":"Bejan","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2026.106227_bib22","article-title":"Distilling large language models for biomedical knowledge extraction: a case study on adverse drug events","author":"Gu","year":"2023","journal-title":"arXiv"},{"key":"10.1016\/j.ebiom.2026.106227_bib23","series-title":"Proceedings of the 9th Machine Learning for Healthcare Conference","article-title":"MALADE: orchestration of LLM-Powered agents with retrieval augmented generation for pharmacovigilance","author":"Choi","year":"2024"},{"key":"10.1016\/j.ebiom.2026.106227_bib24","series-title":"2024 IEEE 12th international conference on healthcare informatics (ICHI)","first-page":"242","article-title":"Assertion detection in clinical natural language processing using large language models","author":"Ji","year":"2024"},{"issue":"4S","key":"10.1016\/j.ebiom.2026.106227_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.02.386","article-title":"Primary analysis of imvigor 210: atezolizumab in platinum-treated advanced urothelial carcinoma: PD27-12","volume":"195","author":"Dreicer","year":"2016","journal-title":"J Urology"},{"issue":"24","key":"10.1016\/j.ebiom.2026.106227_bib26","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1\u2013Selected advanced Non\u2013small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10066","key":"10.1016\/j.ebiom.2026.106227_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"10122","key":"10.1016\/j.ebiom.2026.106227_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106227_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10308","key":"10.1016\/j.ebiom.2026.106227_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10358","key":"10.1016\/j.ebiom.2026.106227_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106227_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41591-024-03425-5","article-title":"The TRIPOD-LLM reporting guideline for studies using large language models","volume":"31","author":"Gallifant","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106227_bib33","doi-asserted-by":"crossref","first-page":"e950","DOI":"10.1093\/oncolo\/oyad135","article-title":"Evaluating survival after hospitalization due to immune-related adverse events from checkpoint inhibitors","volume":"28","author":"Silverstein","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ebiom.2026.106227_bib34","series-title":"Do prompt-based models really understand the meaning of their prompts? Naacl 2022: the 2022 conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies","first-page":"2300","author":"Webson","year":"2022"},{"key":"10.1016\/j.ebiom.2026.106227_bib35","series-title":"True Few-Shot Learning with Language Models. Advances in Neural Information Processing Systems 34","author":"Perez","year":"2021"},{"key":"10.1016\/j.ebiom.2026.106227_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-023-06160-y","article-title":"Health system-scale language models are all-purpose prediction engines","volume":"619","author":"Jiang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2026.106227_bib38","author":"Lab"},{"key":"10.1016\/j.ebiom.2026.106227_bib39","article-title":"LLaMA: open and efficient foundation language models","author":"Touvron","year":"2023","journal-title":"arXiv"},{"key":"10.1016\/j.ebiom.2026.106227_bib40","article-title":"The llama 3 herd of models","author":"Grattafiori","year":"2024","journal-title":"arXiv"},{"key":"10.1016\/j.ebiom.2026.106227_bib41","article-title":"BioGPT: generative pre-trained transformer for biomedical text generation and mining","author":"Luo","year":"2022","journal-title":"arXiv"},{"issue":"7972","key":"10.1016\/j.ebiom.2026.106227_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41586-023-06291-2","article-title":"Large language models encode clinical knowledge","volume":"620","author":"Singhal","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106227_bib43","first-page":"1","article-title":"Pre-train, prompt, and predict: a systematic survey of prompting methods in natural language processing","volume":"55","author":"Liu","year":"2023","journal-title":"ACM Comput Surv"},{"key":"10.1016\/j.ebiom.2026.106227_bib44","series-title":"Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks. Advances in Neural Information Processing Systems 33","author":"Lewis","year":"2020"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106227_bib45","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2589-7500(23)00225-X","article-title":"Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study","volume":"6","author":"Zack","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.ebiom.2026.106227_bib46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2024.13486","article-title":"Addressing AI algorithmic bias in health care","volume":"332","author":"Ratwani","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2026.106227_bib47","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1038\/s41591-024-03258-2","article-title":"A toolbox for surfacing health equity harms and biases in large language models","volume":"30","author":"Pfohl","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106227_bib48","article-title":"Medical ethics of large language models in medicine","volume":"1","author":"Ong","year":"2024","journal-title":"N Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:23:07Z","timestamp":1779564187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642600109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":46,"alternative-id":["S235239642600109X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106227","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106227"}}